Nureca Ltd. (IN:NURECA)
:NURECA
Want to see IN:NURECA full AI Analyst Report?
Top Page
Nureca Ltd.
(NURECA)
Select Model
Select Model
Rating:57Neutral
Price Target:
₹269.00
▼(-9.99% Downside)
Action:ReiteratedDate:12/02/25
Nureca Ltd.'s overall stock score is primarily influenced by its challenging financial performance, marked by negative profitability and cash flow issues. While technical analysis shows positive momentum, the high P/E ratio suggests overvaluation. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Low leverage / strong equity
A ~92% equity ratio and favorable debt metrics provide durable financial flexibility. Low leverage reduces refinancing risk, allows room to fund strategic investments or weather cyclical revenue swings, and supports long-term stability despite near-term operating losses.
Negative Factors
Weak cash generation
Persistent negative operating and free cash flow creates a structural funding gap. This limits ability to finance inventory, marketing, and capex internally, increases dependence on external capital, and raises the risk that growth initiatives cannot be funded sustainably over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong equity
A ~92% equity ratio and favorable debt metrics provide durable financial flexibility. Low leverage reduces refinancing risk, allows room to fund strategic investments or weather cyclical revenue swings, and supports long-term stability despite near-term operating losses.
Read all positive factors
Nureca Ltd. (NURECA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.53B
Dividend YieldN/A
Average Volume (3M)9.27K
Price to Earnings (P/E)20.6
Beta (1Y)1.07
Revenue Growth51.01%
EPS GrowthN/A
CountryIN
Employees138
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)3.73
Shares Outstanding9,541,920
10 Day Avg. Volume526
30 Day Avg. Volume9,266
Financial Highlights & Ratios
PEG Ratio-1.76
Price to Book (P/B)1.13
Price to Sales (P/S)2.00
P/FCF Ratio-9.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nureca Ltd. Business Overview & Revenue Model
Company Description
Nureca Limited, a B2C company, engages in the home healthcare and wellness products business in India. It offers chronic disease products, such as nebulizers, blood pressure monitors, finger pulse oximeter, glucose meter, and thermometer; orthoped...
How the Company Makes Money
Nureca makes money primarily by selling branded health, wellness, and home-care products directly to consumers. Its revenue is generated from product sales under its owned/marketed brands (notably Dr Trust and Dr Physio) across online channels (e-...
Nureca Ltd. Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
65
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.30B | 1.10B | 919.28M | 1.11B | 2.56B | 2.13B |
| Gross Profit | 439.25M | 231.33M | 311.42M | 355.94M | 1.23B | 1.14B |
| EBITDA | 82.58M | 48.95M | 2.41M | -79.04M | 632.04M | 642.33M |
| Net Income | 41.07M | 8.46M | -17.94M | -82.50M | 449.60M | 463.74M |
Balance Sheet | ||||||
| Total Assets | 2.25B | 2.10B | 2.05B | 2.07B | 2.19B | 1.86B |
| Cash, Cash Equivalents and Short-Term Investments | 87.40M | 736.29M | 1.44B | 1.02B | 927.10M | 1.27B |
| Total Debt | 53.92M | 49.66M | 25.16M | 33.27M | 44.05M | 38.85M |
| Total Liabilities | 259.46M | 156.91M | 120.54M | 116.97M | 159.32M | 226.54M |
| Stockholders Equity | 1.99B | 1.94B | 1.93B | 1.95B | 2.03B | 1.63B |
Cash Flow | ||||||
| Free Cash Flow | -10.02M | -234.06M | -37.98M | 98.31M | -46.00M | 341.40M |
| Operating Cash Flow | 44.46M | -190.83M | -27.12M | 102.27M | 13.99M | 348.67M |
| Investing Cash Flow | -67.25M | 84.39M | 175.76M | -164.56M | -30.89M | -1.10B |
| Financing Cash Flow | 2.16M | -1.69M | -13.03M | -15.07M | -73.02M | 923.39M |
Nureca Ltd. Technical Analysis
Positive
298.85
Price Trends
264.61
Negative
277.16
Negative
267.44
Negative
Market Momentum
-0.04
Negative
56.23
Neutral
60.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Positive. The current price of 298.85 is above the 20-day moving average (MA) of 242.38, above the 50-day MA of 264.61, and above the 200-day MA of 267.44, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 56.23 is Neutral, neither overbought nor oversold. The STOCH value of 60.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NURECA.
Nureca Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ₹38.94B | 19.90 | ― | 1.70% | 13.07% | 14.46% | |
57 Neutral | ₹2.53B | 20.62 | ― | ― | 51.01% | ― | |
57 Neutral | ₹22.69B | 20.54 | ― | 0.49% | 1.02% | -24.31% | |
54 Neutral | ₹24.02B | -36.05 | ― | ― | -4.23% | 93.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹19.37B | -18.14 | ― | 0.08% | 1.96% | -970.01% | |
46 Neutral | ₹39.77B | -40.91 | ― | 0.06% | 92.70% | -28.06% |
* Healthcare Sector Average
IN:NURECA
Nureca Ltd.
265.35
36.55
15.97%
IN:ADVENZYMES
Advanced Enzyme Technologies Ltd
347.95
69.83
25.11%
IN:INDOCO
Indoco Remedies Limited
209.90
-19.69
-8.58%
IN:MOREPENLAB
Morepen Laboratories Limited
41.41
-17.59
-29.81%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
498.60
4.40
0.89%
IN:ZOTA
Zota Health Care Ltd.
1,311.20
420.07
47.14%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.